← Holders
Great Point Partners LLC
What Great Point Partners LLC reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 1281446 · Filed Nov 16, 2026
- Positions
- 45
- Reported value
- $418.5M
- Opened
- 12
- Closed
- 9
- Other managers included
- 2
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
Quarters on file
- Sep 30, 2025$242.5M30 positions
- Dec 31, 2025$308.4M29 positions
- Mar 31, 2026$435.1M42 positions
- Jun 30, 2026$529.1M42 positions
- Sep 30, 2026$418.5M45 positions
| Security | Shares | Change | Value | Of portfolio |
|---|---|---|---|---|
| 3M | ±0% | $28.3M | 6.8% | |
VERAVera Therapeutics, Inc. | 808.7K | +34.6% | $26.1M | 6.2% |
VORVor Biopharma Inc. | 1.1M | −33.7% | $21.5M | 5.1% |
AMLXAmylyx Pharmaceuticals, Inc. | 700K | ±0% | $20.4M | 4.9% |
SGMTSagimet Biosciences Inc. | 2M | −3.4% | $19.4M | 4.6% |
DFTXDefinium Therapeutics, Inc. | 508.7K | +19.7% | $19.4M | 4.6% |
IONSIonis Pharmaceuticals Inc | 420K | New | $18.8M | 4.5% |
GMABGenmab A/S | 525K | New | $18.7M | 4.5% |
SLGLSol-Gel Technologies Ltd. | 239.2K | −12.8% | $17.8M | 4.2% |
ZURAZura Bio Ltd | 4.1M | −3.3% | $17M | 4.1% |
LBRXLB Pharmaceuticals Inc | 410.4K | +29.4% | $15.8M | 3.8% |
ABVXAbivax S.A. | 155K | −24.1% | $15.3M | 3.7% |
ANNXAnnexon, Inc. | 3.5M | ±0% | $14.8M | 3.5% |
BLTEBelite Bio, Inc | 75K | New | $12.7M | 3% |
EPRXEupraxia Pharmaceuticals Inc. | 1.2M | ±0% | $10.9M | 2.6% |
NKTRNektar Therapeutics | 175K | ±0% | $10.6M | 2.5% |
MLTXMoonLake Immunotherapeutics | 855.8K | ±0% | $10M | 2.4% |
CLYMClimb Bio, Inc. | 800K | −20.0% | $9.2M | 2.2% |
ABCLAbCellera Biologics Inc. | 600K | New | $8.8M | 2.1% |
NGNENeurogene Inc. | 300K | −14.8% | $8.3M | 2% |
CMPSCOMPASS Pathways plc | 500K | New | $6.2M | 1.5% |
JATTJATT II Acquisition Corp. | 500K | ±0% | $5.6M | 1.3% |
IFRXInflaRx N.V. | 3M | ±0% | $5.5M | 1.3% |
RACCResearch Alliance Corp III | 504.9K | New | $5.5M | 1.3% |
DRUGBright Minds Biosciences Inc. | 109.6K | ±0% | $5.5M | 1.3% |
AMANAmanat Acquisition Corp. | 500K | ±0% | $5.3M | 1.3% |
ALTAltimmune, Inc. | 1.7M | ±0% | $5M | 1.2% |
JTTTJATT III Acquisition Corp | 450K | New | $5M | 1.2% |
| 150K | New | $4.8M | 1.1% | |
SCYXScynexis Inc | 944.3K | ±0% | $4.7M | 1.1% |
CGEMCullinan Therapeutics, Inc. | 300K | ±0% | $4.6M | 1.1% |
| 300K | New | $4M | 1% | |
HELPHelus Pharma Inc. | 321K | New | $3.9M | 0.9% |
RZLTRezolute, Inc. | 951.8K | ±0% | $3.9M | 0.9% |
IRDOpus Genetics, Inc. | 776.9K | −60.6% | $3.8M | 0.9% |
ELVNEnliven Therapeutics, Inc. | 70K | ±0% | $3.2M | 0.8% |
RLMDRelmada Therapeutics, Inc. | 842.1K | ±0% | $3.2M | 0.8% |
DBVTDBV Technologies S.A. | 250K | +59.3% | $2.9M | 0.7% |
EVMNEvommune, Inc. | 325K | ±0% | $2.7M | 0.6% |
CTNMContineum Therapeutics, Inc. | 186.2K | −79.8% | $2.5M | 0.6% |
ORKAOruka Therapeutics, Inc. | 24.6K | −86.6% | $2.1M | 0.5% |
HUMAHumacyte, Inc. | 3.8M | ±0% | $1.9M | 0.5% |
RNTXRein Therapeutics, Inc. | 1.7M | −35.4% | $1.3M | 0.3% |
RACDResearch Alliance Corp IV | 106.4K | New | $1.3M | 0.3% |
| 97.3K | New | $411.6K | 0.1% |